Agios Pharmaceuticals, Inc. Common Stock Offering

Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 9,487,500 shares of common stock of Agios Pharmaceuticals, Inc. for approximately $294.1 million before underwriting discounts and estimated expenses of the offering. Included in the shares are 1,237,500 shares sold by Agios pursuant to the underwriters’ exercise in full of their option to purchase additional shares. The common stock is listed on the Nasdaq Global Select Market under the symbol “AGIO.”

Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism and adjacent areas of biology. All Agios programs focus on genetically identified patient populations, leveraging its knowledge of metabolism, biology and genomics.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associate Chris Van Buren. The tax team included partner Michael Mollerus and associate Joseph M. Gerstel. Counsel Bonnie Chen and associate Christopher C. Woller provided intellectual property and technology advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.